DEA Plays Whack-A-Mole With Unpronounceable Designer Drug
Published Date: 12/11/2025
Rule
Summary
The DEA is extending the temporary ban on MDMB-4en-PINACA, a powerful synthetic drug, keeping it in the strictest control category (Schedule I) for another year until December 12, 2026, or until a permanent decision is made. This means anyone making, selling, or using this drug faces serious legal consequences. The extension helps keep communities safe while the government finishes its review.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Schedule I Status Extended One Year
The DEA extended the temporary Schedule I listing for MDMB-4en-PINACA effective December 12, 2025 through December 12, 2026, or until a permanent decision is made. That means anyone who makes, sells, imports, exports, or possesses this drug continues to face the regulatory controls and civil and criminal penalties that apply to Schedule I substances.
Research and Teaching Still Restricted
Researchers, educators, and laboratories that engage in research, instructional activities, or chemical analysis involving MDMB-4en-PINACA remain subject to Schedule I controls and to the same administrative, civil, and criminal sanctions. Those activities remain restricted under this temporary order for the one-year extension.
Salts and Isomers Also Controlled
The temporary extension explicitly covers MDMB-4en-PINACA as well as its salts, isomers, and salts of isomers whenever such variants exist. That means chemical variants of MDMB-4en-PINACA are treated the same as the named compound under Schedule I during the extension period.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-22518 — Safety Zone; Patapsco River, Baltimore, MD
On December 13, 2025, from 9:30 to 10:30 p.m., the Coast Guard is setting up a temporary safety zone around a barge in Baltimore’s Patapsco River for a fireworks show. Boats and people can’t enter this 300-foot zone unless the Coast Guard says it’s okay. This keeps everyone safe from fireworks hazards without causing any fees or long delays.
Next: 2025-22545 — Magnuson-Stevens Act Provisions; Fisheries of the Northeastern United States; Fisheries of the Northeastern United States; 2025-2027 Atlantic Herring Fishery Specifications
Starting December 11, 2025, Atlantic herring fishers in the Northeast get a big boost with catch limits rising up to 237% for 2026 and 2027! These changes help protect herring populations while letting fishermen catch more, based on fresh science. This means a healthier ocean and better fishing opportunities for the next three years.